Why man’s best friend, the dog, could also benefit from an anti-HER-2 vaccine (Review)

Judit Fazekas, Irene Fürdös, Josef Singer, Erika Jensen-Jarolim*

*Corresponding author for this work

Research output: Journal article (peer-reviewed)Review article

12 Citations (Scopus)


Human epidermal growth factor receptor-2 (HER-2) is a well-established target for anticancer precision medicine in humans. A HER-2 homologue with 92% amino acid identity has been described in canine mammary tumors, which is termed here as ‘dog epidermal growth factor receptor-2 (DER-2)’, with similar biological implications as those in human breast cancer. Both antigens can principally be immunologically targeted by anti-HER-2 antibodies, such as trastuzumab; however, the in vivo application of humanized antibodies to other species would lead to specific hypersensitivity reactions. Therefore, HER-2 mimotope vaccines that actively induce autologous trastuzumab-like immunoglobulins represent a novel and economic treatment option to overcome species-specific limitations. Thus, the present review proposes the implementation of clinical trials with HER-2 vaccines in canine cancer model patients with spontaneous DER-2 positive mammary gland carcinomas in order to assess their safety and efficacy. This approach would not only pave the way into the veterinary oncology market, but would also similarly generate robust data for human trials and facilitate the testing of novel combinatorial treatments.

Original languageEnglish
Pages (from-to)2271-2276
Number of pages6
JournalOncology Letters
Issue number4
Publication statusPublished - Oct 2016
Externally publishedYes


  • Cancer vaccine
  • Dog
  • HER-2
  • Mimotope
  • Oncology
  • Translational

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Why man’s best friend, the dog, could also benefit from an anti-HER-2 vaccine (Review)'. Together they form a unique fingerprint.

Cite this